Everolimus plus early tacrolimus minimization: A phase III, randomized, open-label, multicentre trial in renal transplantation

Transplant International

Volumn 25, Issue 5, 2012, Pages 592-602

  Langer, Robert M ^a   Hené, Ronald ^b   Vitko, Stefan ^c   Christiaans, Maarten ^d   Tedesco Silva, Helio ^e   Ciechanowski, Kazimierz ^f   Cassuto, Elisabeth ^g   Rostaing, Lionel ^h   Vilatoba, Mario ⁱ   MacHein, Uwe ^j   Ulbricht, Bettina ^j   Junge, Guido ^j   Dong, Gaohong ^j   Pascual, Julio ^k  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^f Department of Nephrology Transplantology and Internal Medicine ^*  (Poland)

^g PASTEUR HOSPITAL   (France)

^h CHU RANGUEIL   (France)

ⁱ INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^j NOVARTIS PHARMA AG   (Switzerland)

^k HOSPITAL DEL MAR   (Spain)

more..

Author keywords

calcineurin inhibitor minimization; everolimus; mammalian target of rapamycin inhibitor; proliferation signal inhibitors; tacrolimus

Indexed keywords

BASILIXIMAB; EVEROLIMUS; PREDNISONE; TACROLIMUS;

ACNE; ADULT; ALOPECIA; ANEMIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DRUG EXPOSURE; DRUG POTENTIATION; DRUG RESEARCH; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FEMALE; FEVER; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; INSOMNIA; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PILOT STUDY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREMOR; URINARY TRACT INFECTION;

ADULT; CALCINEURIN; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859711356     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01465.x     Document Type: Article

References (31)

1. Zeier M, Dohler B, Opelz G, Ritz E,. The effect of donor gender on graft survival. J Am Soc Nephrol 2002; 13: 2570.
2. Chapman JR, Valantine H, Albanell J, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007; 39: 2937.
3. Pascual J, Marcen R, Ortuno J,. Renal function: defining long-term success. Nephrol Dial Transplant 2004; 19 (Suppl. 6): vi3.
4. Nankivell BJ, Chapman JR,. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006; 81: 643.
5. Jevnikar AM, Mannon RB,. Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol 2008; 3 (Suppl. 2): S56.
6. Veroux M, Corona D, Giuffrida G, et al. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transplant Proc 2008; 40: 1885.
7. Baboolal K,. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003; 75: 1404.
8. Frimat L, Cassuto-Viguier E, Charpentier B, et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant 2006; 6: 2725.
9. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP,. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560.
10. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J,. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777.
11. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
12. Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532.
13. Pascual J, Boletis IN, Campistol JM,. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant Rev 2006; 20: 1.
14. Tedesco-Silva Jr H., Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401.
15. Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85: 821.
16. Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A,. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006; 38: 3456.
17. Frei U, Daloze P, Vitko S, et al. Acute rejection in low-toxicity regimens: clinical impact and risk factors in the Symphony study. Clin Transplant 2010; 24: 500.
18. Jain A, Kashyap R, Dodson F, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation 2001; 72: 1091.
19. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
20. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
21. Dunn C, Croom KF,. Everolimus: a review of its use in renal and cardiac transplantation. Drugs 2006; 66: 547.
22. Demopoulos L, Polinsky M, Steele G, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008; 40: 1407.
23. Haririan A, Morawski K, West MS, et al. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant 2007; 21: 466.
24. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006; 81: 845.
25. Kahan BD,. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194.
26. Mora PF,. New-onset diabetes after renal transplantation. J Investig Med 2010; 58: 755.
27. Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009; 9: 1607.
28. Knight SR, Russell NK, Barcena L, Morris PJ,. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009; 87: 785.
29. Knoll GA, MacDonald I, Khan A, Van WC,. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
30. Salifu MO, Jindal RM,. Mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant patients. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 29.
31. US National Institute of Health. Clinical trial number NCT00170833. US National Institute of Health [cited 2 August 2010]. Available at: www clinicaltrials gov/ct2/show/NCT00170833 2010.